Boston, MA 10/01/2013 (wallstreetpr) – On September 20, Cerus Corporation (NASDAQ:CERS) stock charted close to 6% increase in value from its previous day’s close. At current valuations, the stock is trading at 4.5% above its prior 52 week high valuations and is up 150% from its 52 week lowest pricing point. Company attracted undue attention on the browsers yesterday with over 946,503 shares getting sold across the counter. The volume was almost twice that of its daily average. It has appreciated by close to 50% in the past 90 days.
Over the past 12 months the company stock has managed to grow from strength to strength. It has gained close to 98% in its market value over the past 12 months with a market capitalization of close to $468 million. Over a 12 month trailing period, the firm has clocked $38 million in sales and has accumulated a net loss of $22 over the same period. It has a total of 69 million outstanding shares which are trading at $6.72 per share as of close of business on September 30.
Operations
Cerus Corporation is a biopharma company with blood safety as it chosen area of focus. It has developed “INTERCEPT Blood System” which has proved effective in arresting the spread of a wide range of viruses and other harmful parasites like that come along with donated blood. Its screening mechanism effectively blocks out pathogens which cause hepatitis B and HIV. It is also very effective in “tackling influenza, malaria and dengue”.
The “INTERCEPT Blood System” is currently sold in Europe. It is being used in screening both blood platelets and plasma. It also has a big market in Middle East. Based on its strong usage and performance in Europe, Cerus is pushing hard for a regulatory approval for “INTERCEPT Blood System” to be sold in North America.
